Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Fulgent Genetics's share price for the quarter that ended in Dec. 2024 was $18.47. Fulgent Genetics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 30.8 Mil. Therefore, Fulgent Genetics's market cap for the quarter that ended in Dec. 2024 was $569.6 Mil.
Fulgent Genetics's quarterly market cap
increased
from Jun. 2024 ($593.7 Mil) to Sep. 2024 ($663.6 Mil) but then
declined
from Sep. 2024 ($663.6 Mil) to Dec. 2024 ($569.6 Mil).
Fulgent Genetics's annual market cap
declined
from Dec. 2022 ($876.7 Mil) to Dec. 2023 ($857.3 Mil) and
declined
from Dec. 2023 ($857.3 Mil) to Dec. 2024 ($569.6 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Fulgent Genetics's Enterprise Value for Today is $266.4 Mil.
Fulgent Genetics Market Cap Historical Data
The historical data trend for Fulgent Genetics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fulgent Genetics's Market Cap
For the Diagnostics & Research subindustry, Fulgent Genetics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Market Cap distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Market Cap falls into.
Fulgent Genetics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Fulgent Genetics's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics (NAS:FLGT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Fulgent Genetics Market Cap Related Terms
Thank you for viewing the detailed overview of Fulgent Genetics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FLGT has been successfully added to your 